Patient enrollment in a phase 1 clinical trial of PolyActiva’s biodegradable, slow-release ocular implant for the treatment of glaucoma has been completed, the company announced in a press release.
The study is evaluating the safety and tolerability of the Latanoprost FA SR implant, which is designed to provide a constant daily dose of latanoprost free acid for at least 30 weeks.
“To date, our phase 1 study has demonstrated that our implant is safe and well tolerated and provides treatment for a 6-month period before it biodegrades completely. We have (Read more...)
Uncategorized